TRYAL, Inc., a protocol-informed eClinical automation software company, announces the addition of Amanda Nite to its executive team as Senior Vice President of Operations & Product.
In this role, Ms. Nite will be responsible for leading the development and execution of the company's product strategy as well as driving operational excellence. She will be focused on delivering products and services across TRYAL’s innovative platform that exceed customer expectations and drive the company's growth.
With more than 20 years of clinical & technical operations experience, Amanda has held roles in global life science organizations providing technology solutions to the industry including Oracle, Medidata, Altavoz, Bioclinica, ICON plc and GSK.
"I am excited to join the talented team at TRYAL who are building solutions to address long-standing, unmet needs in the market. The clinical trial landscape is ripe for improvement and I believe Tryal is poised to quickly make a difference." said Ms Nite.
“It’s a real privilege to add Amanda to our executive team,” says Shae Wilkins, CEO, TRYAL. “We are committed to ensuring an optimal experience for sponsors, partners and their study participants. Under Amanda’s leadership, we will make strategic decisions about investments and operational processes that will serve our clients’ ever-evolving needs and measure the impact of our business. Amanda’s depth of expertise allows us to continue enhancing our products, processes, and services to meet the needs of these crucial stakeholders throughout a clinical trial.”
To learn more about TRYAL and their leadership team, view their profiles at About Us.
TRYAL was founded on the principle that the path between the protocol and your submission, in today's rapidly evolving eClinical ecosystem, is too complex, lacks transparency, and is starving for critical automation. Our heritage is in bringing automation-driven innovation to eClinical systems. Our founders have been a part of the eClinical industry supporting a myriad of clinical trials for the past 22 years…Our most recent advancements will have the greatest impact of all, making clinical trials faster, easier and simpler for everyone.